静脉重组组织型纤溶酶原激活剂对机械取栓治疗前循环缺血性卒中结局的影响
这项前瞻性观察性队列研究纳入2012年1月至2017年1月在法国里尔大学医院因前循环大动脉闭塞接受机械取栓的485例患者,其中348例(72%)接受静脉溶栓联合机械取栓,137例(28%)仅接受机械取栓。结果显示静脉溶栓联合机械取栓组3个月良好功能结局比例更高(35%对22%,调整相对危险度1.76,95%置信区间1.23-2.55),3个月内死亡率更低(14%对32%,调整相对危险度0.46,95%置信区间0.31-0.70),成功再灌注更常见(75%对60%,调整相对危险度1.30,95%置信区间1.11-1.53),两组出血并发症无差异。
要点
- 静脉溶栓联合机械取栓组良好功能结局35%,仅机械取栓组22%,调整相对危险度1.76(95%置信区间1.23-2.55)。
- 静脉溶栓联合机械取栓组3个月内死亡率14%,仅机械取栓组32%,调整相对危险度0.46(95%置信区间0.31-0.70)。
- 静脉溶栓联合机械取栓组成功再灌注75%,仅机械取栓组60%,调整相对危险度1.30(95%置信区间1.11-1.53)。
核心结论
- 在该人群中,机械取栓前接受静脉溶栓改善了3个月功能结局和生存率。
- 在等待随机对照试验期间,该结果鼓励不要避免机械取栓前进行静脉溶栓。
研究设计与样本
- 前瞻性观察性队列研究,纳入2012年1月至2017年1月在法国里尔大学医院因前循环大动脉闭塞接受机械取栓的485例患者,中位年龄68岁,46%为男性,348例(72%)在静脉溶栓联合机械取栓组,137例(28%)在机械取栓组。
主要发现
- 机械取栓组良好功能结局22%,静脉溶栓联合机械取栓组35%(调整相对危险度1.76;95%置信区间1.23-2.55)。
- 3个月内死亡在静脉溶栓联合机械取栓组更少(14%对32%;调整相对危险度0.46;95%置信区间0.31-0.70)。
- 成功再灌注(脑梗死溶栓量表2b-3级)在静脉溶栓联合机械取栓组更常见(75%对60%;调整相对危险度1.30;95%置信区间1.11-1.53)。
- 两组出血并发症无差异。
临床怎么用
- 作者认为,在等待随机对照试验期间,该结果鼓励不要避免机械取栓前进行静脉溶栓。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Intravenous thrombolysis (IVT) followed by mechanical thrombectomy (MT) improves functional outcome in patients with ischemic stroke related to proximal-vessel occlusion in the anterior circulation. Whether MT alone is as effective as IVT/MT remains controversial. We aimed at evaluating the influence of IVT in patients with large anterior circulation artery occlusion treated with MT. METHODS: We did a prospective observational cohort study in patients with stroke related to large anterior circulation artery occlusion treated by MT who were admitted to Lille University Hospital, Lille, France. We evaluated the influence of IVT on favorable functional outcome (defined as a modified Rankin Scale score 0-2 or similar to the prestroke modified Rankin Scale) and on mortality at month 3. Between-group comparisons in outcomes were adjusted for prespecified confoundors by using a propensity score-adjusted approach. RESULTS: From January 2012 to January 2017, we included 485 patients (median age, 68 years; 46% men; 348 [72%] in the IVT/MT group; 137 [28%] in the MT group). In MT group, 22% of patients had a favorable outcome versus 35% in IVT/MT group (adjusted relative risk, 1.76; 95% confidence interval, 1.23-2.55). Mortality within 3 months occurred less frequently in IVT/MT group (14% versus 32%; adjusted relative risk, 0.46; 95% confidence interval, 0.31-0.70). Successful reperfusion (Thrombolysis in Cerebral Infarction scale 2b-3) was more frequent in IVT/MT group (75% versus 60%; adjusted relative risk, 1.30; 95% confidence interval, 1.11-1.53). There was no difference between groups on hemorrhagic complications. CONCLUSIONS: In this population, previous IVT improved functional outcome and survival at 3 months in patients treated by MT. While waiting for randomized controlled trials, this result encourages not to avoid IVT before MT.
引用
- Ferrigno M, Bricout N, Leys D, et al. Intravenous Recombinant Tissue-Type Plasminogen Activator: Influence on Outcome in Anterior Circulation Ischemic Stroke Treated by Mechanical Thrombectomy. Stroke. 2018. PMID: 29748424. doi:10.1161/STROKEAHA.118.020490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。